April 01, 2026

Evolocumab Reduced CV Events in Diabetes

Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering

Conexiant

April 01, 2026

Tirzepatide Linked to Lower Cardiorenal Events

Researchers evaluate expanded six-component outcome in high-risk patients with diabetes

Conexiant

March 30, 2026

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.

Conexiant

March 30, 2026

Neurofilament Levels Linked to AF Risk

Higher levels associated with stroke, death, and heart failure in long-term cohort

Conexiant

March 27, 2026

ACSM Revises Resistance Training Guidance

Synthesized evidence clarifies which training variables enhance strength, hypertrophy, and performance.

Conexiant

March 24, 2026

Mammography AI Spots Vascular Signals

Routine breast imaging offers opportunity for cardiovascular risk assessment.

Conexiant

March 18, 2026

Penetrating Neck Trauma Triage Shifts

CT angiography and clinical signs refine triage and management.

Conexiant

March 17, 2026

Aneurysmal Hemorrhage Triggers Systemic Effects

Researchers examine physiologic responses following rupture and link them to outcomes.

Conexiant

March 17, 2026

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Conexiant

March 16, 2026

AF Stroke Prevention: Testing Ablation

In the randomized STABLED trial, adding catheter ablation to edoxaban did not reduce recurrent stroke or major cardiovascular outcomes.

Conexiant